Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 StudyOriginal Research · 2012 · 187 citations
2Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow‐positive <scp>B</scp>urkitt lymphoma/leukaemia: a Children's Oncology Group ReportOriginal Research · 2014 · 131 citations
3Overall survival of children and adolescents with mature B cell non‐Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with <scp>FAB</scp>/<scp>LMB</scp> 96: A report from the <scp>FAB</scp>/<scp>LMB</scp> 96 study groupPrognostic Study · 2018 · 59 citations
4Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsOriginal Research · 2006 · 363 citations
5Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962Cohort Study · 2010 · 65 citations

More from Leukemia & lymphoma/Leukemia and lymphoma

More from Cornell University